title: Question: does isosorbide dinitrate/hydralazine therapy benefit systolic heart failure patients with renal insufficiency?
authors.affiliation: University of Oklahoma Health Sciences Center, Tulsa, USA.
authors.forename: Lu
authors.initials: L
authors.lastname: Pan
authors.forename: Josh
authors.initials: J
authors.lastname: Payne
authors.forename: Mel
authors.initials: M
authors.lastname: Clark
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D019317:Evidence-Based Medicine; D054143:Heart Failure, Systolic / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D051437:Renal Insufficiency / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D004338:Drug Combinations; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D007548:Isosorbide Dinitrate